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The kinetics of metabolic and inﬂammatory parameters associated with obesity were evaluated in a murine diet-induced obesity
(DIO) model using a diet high in fat and cholesterol. Cellular inﬁltration and mediator production were assessed and shown
to be therapeutically modulated by the PPARgamma agonist rosiglitazone. C57BL/6 mice were maintained on a 45% fat/ 0.12%
cholesterol (HF/CH) or Chow diet for 3, 6, 16, or 27 weeks. Flow cytometry was employed to monitor peripheral blood monocytes
and adiposetissuemacrophages (ATM).Gene expression and protein analysis methods wereused to evaluate mediator production
from total epididymal fat (EF), stromal vascular fraction (SVF), and sorted SVF cells. To investigate therapeutic intervention, mice
were fed a HF/CH diet for 12 weeks and then a diet formulated with rosiglitazone (5mg/kg) for an additional 6 weeks. A HF/CH
diet correlated with obesity and a dramatic proinﬂammatory state. Therapeutic intervention with rosiglitazone attenuated the
HF/CHinducedinﬂammation.Inaddition,anovelpopulationwasfoundthatexpressedthehighestlevelsofthepro-inﬂammatory
mediators CCL2 and IL-6.
1.Introduction
In a Western society, where diets are generally high in fat and
cholesterol, 33% of adults and 17% of children have been
classiﬁed as obese [1, 2]. Obesity and its associated disorders,
including insulin resistance, type II diabetes, nonalcoholic
fatty liver disease, and atherosclerosis, are growing medical
concerns [3]. Chronic low-grade inﬂammation is proposed
as an important link between obesity and its associated
pathologies [1, 3, 4]. Data from both humans [5, 6]a n dm i c e
[6–9] have shown a positive correlation between increasing
BMI body mass index (BMI) and hyperinsulinemia, and
macrophage content in the adipose tissue.
In both human [6, 10, 11]a n dm o u s e[ 6, 8, 9, 12–
14], various studies have shown an inﬂammatory reaction
in adipose tissue characterized by macrophage accumulation
and increased levels of mediators including TNFα,I L - 1 β,
IL-6, IL-10, and MCP-1. Macrophages are proposed to
be a major source of pro-inﬂammatory mediators, and
the current dogma suggests the existence of two sub-
sets of murine adipose tissue macrophages (ATM). Pro-
inﬂammatory macrophages (PI-ATM) express TNFα,I L -
1β, IL-4, IL-6, CCL2, and CCR2, and the alternatively acti-
vated/resident macrophages (R-ATM) express IL-10, ApoE,
and arginase [6, 8, 9, 12–14]. In contrast, human ATMs
have been reported to have an alternatively activated surface2 PPAR Research
phenotype, yet secrete both pro- and anti-inﬂammatory
mediators. [11, 15, 16].
Currently, most of the murine models of obesity used
to study the inﬂammatory component of obesity have
employed diets rich in fat only. However, humans often
c o n s u m ed i e t st h a ta r er i c hi nc h o l e s t e r o la sw e l la sf a t
that are associated not only with obesity but also with two
comorbidities of obesity such as nonalcoholic fatty liver
disease (NAFLD) and atherosclerosis both of which are also
associated with underlying chronic low grade inﬂammation
[3, 4, 17–19]. NAFLD is also associated with insulin resis-
tance [17]. It has been reported previously that feeding mice
a high-fat and cholesterol (HF/CH) diet has been shown to
induce obesity as well as elevate systemic levels of alanine
aminotransferase (ALT) and cause liver damage, indicative
of nonalcoholic fatty liver disease (NAFLD) [2]. Our goal
was to deﬁne the impact of a high-fat and cholesterol diet in
the DIO model on inﬂammatory and metabolic parameters
by proﬁling mediator production and by monitoring the
modulation of peripheral and adipose tissue immune cells.
Although it has been shown in both rodents and humans
that diet and/or exercise can modulate certain inﬂammatory
parameters [20–23], in some cases pharmacologic interven-
tion may still be necessary. Therefore, the second aim was
to determine the utility of the model for discovery of type
II diabetes and metabolic syndrome drugs by evaluating
a known clinical glycemic modulating drug, rosiglitazone.
Recent studies have shown that in addition to modulating
glycemic levels, rosiglitazone also has immunomodulatory
activity in adipose tissue [8, 24–27].
Themanuscriptdescribesthekineticsofmultipleinﬂam-
matory parameters associated with the development of obe-
sity. Speciﬁcally, we assessed the kinetics of blood monocytes
and ATMs from DIO mice, and the modulation of these
leukocytes by rosiglitazone. Furthermore, we report on the
identiﬁcation of two novel adipose tissue cellular inﬁltrates
capable of producing inﬂammatory mediators.
2.MaterialsandMethods
2.1. Model Establishment. C57Bl/6 mice (Charles River) at 6-
weeks of age were placed either on a high-fat diet consisting
of 45% fat and 0.12% cholesterol (D0401280, Research Diets
Inc, New Brunswick, NJ) or a Chow diet (PicoLab 5053,
Lab Diet) (Table 1). The high-fat diet from Research Diets
Inc. is built on their basic diet D12451 with the protein
content at 20%kcal, the carbohydrates 35%kcal, and the fat
45%kcal.Thefattyacidproﬁleofthisdietis36.3%saturated,
45.3% monosaturated, and 18.5% polyunsaturated fat. The
diet intake per mouse per day is ∼3 grams or 14.16kcal per
day (4.72kcal/gm ∗ 3 grams). Animals were on a 12:12
light dark cycle and given food ad libitum. Experiments were
conductedunder our institutional guidelines forthe humane
treatment of laboratory animals.
Metabolic parameters and ﬂow cytometric analysis were
assessed on two separate cohorts of animals from the same
study. All animals were analyzed for changes in body weight
(BW), epididymal fat pad mass, and total fat and lean mass.
Table 1: Composition of rodent diets.
Chow diet HF/CH diet
Ingredients (% kcal)
Protein 24.7 20
Carbohydrates 62.1 35
Fat 13.2 45
Total 100 100
kcal/gm 3.85 4.72
Total cholesterol (% of diet) 0 0.12
Chow: Cat # 5053 PicoLab Rodent Diet 20.
HF/CH: high-fat/cholesterol diet; Cat # D04012801 Research Diets Inc.
Total fat and lean mass were determined 1 week prior to each
termination time point using the EchoMRI-100 for mice
(ECHOMRI, Echo Medical Systems, LLC Houston TX).
Rosiglitazone was formulated at 5mg/kg into the diet
calculated on the basis of predetermined food intake per
mouse (∼3 grams). The dose of 5mg/kg was chosen based
on in-house data demonstrating signiﬁcant improvement in
insulin sensitivity as assessed by insulin tolerance test (ITT).
Animals were fed an HF/CH diet for 12 weeks before being
switched to the HF/CH diet with drug for an additional 6-
weeks. Food was available ad libitum for the mice. Insulin
and leptin levels were measured prior to initiation of drug
dosing and then again at termination.
2.2. Metabolic Parameters. Serum samples were collected
into T-MG Capiject tubes (Terumo Medical Corp, Elkton,
MD) via cardiac puncture. Serum samples were analyzed
using MesoScale Diagnostics assays (Meso Scale Discovery,
Gaithersburg, MD): pro-inﬂammatory mediator kit (Cat
# K11012b-2), adiponectin kit (Cat # K112BXC-2), and a
custom metabolic multiplex (IL-6, GM-CSF, insulin, leptin,
resisten, and TNFα). Insulin and leptin were nonfasting
levels measured at termination. ALT was assessed by an ALT
enzymatic assay (Catachem # C164-02 Bridgeport, CT).
The epididymal fat pads were collected in KHB buﬀer
(Krebs-bicarbonate-HEPES, pH7.4) (Celsis In Vitro Tech-
nologies, Chicago, IL) containing 4% essentially fatty acid-
free bovine serum albumin (Sigma-Aldrich, St. Louis,
MO) 5mM glucose (Sigma-Aldrich), and 1 X Penicillin-
Streptomycin (Invitrogen Corporation, Carlsbad, CA). The
tissue was digested with the described buﬀer using 1mg/ml
collagenase type 1 (Worthington Biochemical Corp. Lake-
wood, NJ) with 0.1mg/ml DNase-1 (Sigma-Aldrich) and
then passed through a 250μm nylon mesh (Small Parts, Inc.,
Miramar, FL) and a 100μm cell strainer (BD Biosciences,
Bedford MA). After centrifugation, the pellet containing the
SVF was resuspended in RPMI 1640 (Invitrogen) containing
10% FBS (Gemini Bio-Products, West Sacramento, CA),
and penicillin/streptomycin (Invitrogen), and washed twice.
1 × 105 cells were added per well in a 48 well tissue culture
plate and incubated at 37◦C, 5% CO2 for 24 hours. Culture
supernatants were analyzed using MesoScale Diagnostics
multiplex kits (Meso Scale Discovery, Gaithersburg, MD).
Statistical analysis was determined by use of the Mann-
Whitney U test.PPAR Research 3
2.3.AnalysisofBloodandSVFSubpopulationsbyFlowCytom-
etry. Epididymal fat was excised and weighed. The SVF was
isolated from the epididymal fat using a 45 minute collage-
nase incubation according to a previously published method
[12] and personal communication. Blood was collected from
mice into T-MQK Capiject tubes (Terumo Medical Corp)
via cardiac puncture. SVF cells or blood leukocytes were
blockedwithCD16/CD32(clone2.4G2,BDBiosciences)and
stainedwithantibodies.Forcellsorting,SVFcellsuspensions
were lysed using RBC Lysis buﬀer (eBiosciences San Diego,
CA) prior to staining; otherwise whole blood and SVF
cells were stained and then lysed with BD FACS Lysing
solution (BD Pharmingen). Monoclonal antibodies to the
following mouse surface antigens were purchased from BD
Biosciences CA: Ly6G (1A8), CD11c (HL3), CD3 (145-
2C11), B220 (RA-6B2), NK1.1 (PK136), CD45 (30-F11),
CD90.2 (53-2.1), CD11b (M1/70), Ly6C (AL-21). Addition-
ally, monoclonal antibodies used were CD62L (clone MEL-
14 Invitrogen) and F480 (clone BM8 Ebioscience). Events
wereacquiredonaBectonDickinson FACsAriaandanalyzed
with FACsDiva Software (BD Biosciences). Sorted cells were
collected, pelleted, and stored at −80◦C. SVF and blood cells
were enumerated with the BD TruCount protocol (Cat #
340498), utilizing the nuclear dye (Control reagent B), and
adding antimouse CD45 (BD Biosciences; 30-F11); human
antibodies in the kit did not interfere with the detection
of mouse CD45 positive leukocytes. Samples were acquired
until4000beadswerecollected,andleukocytesweredetected
by DNA content and CD45.
2.4. RNA Isolation from Epididymal Fat Pad and Quanti-
tative RT-PCR. Epididymal fat tissues were snap-frozen in
liquid nitrogen and stored at −80◦C. Frozen tissue pieces
(<100mg)wereplacedin1mlofQiagenQIAzollysisreagent
(Cat # 79306) containing one sterile 5mm stainless steel
ball, and homogenized using two 1-minute cycles at 20Hz
on a TissueLyser (Qiagen, Valencia CA). Total RNA was
isolated using Qiagen RNeasy Lipid Tissue mini kit (Cat
# 74804) using the additional DNase step according to
manufacturer’s protocol. RNA was eluted from the column
in 60ul RNase free water and quantiﬁed using Nanodrop
1000 v3.3.0 software. cDNA was synthesized using Applied
Biosystems High Capacity cDNA reverse transcriptase kit
(Cat # 4368813) and quantitated with an 18S standard curve
using a TaqMan gene expression assay. Quantitative real-
time PCR utilized a custom made TaqMan Low Density
Array (TLDA) from Applied Biosystems. 100ng cDNA was
loaded in a 100ul volume for each port of the TLDA plates.
Thermal cycling was performedusing an ABI Prism 7900HT
Sequence Detection System and data was analyzed using SDS
v2.2software.TheCtvalueofeachgeneisnormalizedto18S
to obtain ΔCt.
2.5. RNA Isolation and Quantitative PCR for Sorted Cell
Subsets. Total RNA was prepared using the RNAqueous-
Micro kit (Ambion, Austin, TX) according to the manufac-
turer’sinstructions.TaqManprimersandprobes(seeSupple-
mentary Table 1 available at doi:10.1155/2010/970164) were
designedwithUniversalProbeLibraryAssayDesignsoftware
(Roche, Indianapolis, IN) and purchased from IDT or from
Roche, respectively. The PCR reactions were prepared using
the components from the iScript Custom One-Step RT-PCR
KitwithROXandassembledaccordingtothemanufacturer’s
instructions (Quanta BioSciences, Gaithersburg, MD). The
ﬁnal concentrations of the primers and probe in the PCR
reactions were 200nM and 100nM, respectively. The ﬂuoro-
genic probes were labeled with 6-carboxyﬂuorescein (6FAM)
as the reporter and a nonﬂuorescent quencher. Each 10μl
PCR reaction contained 2μl (10ng) of total RNA. Thermal
cycling was performed on an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA)
according to the following protocol: one ten-minute cycle at
50◦C, followed by one ﬁve-minute cycle at 95◦C, followed by
forty ﬁfteen-second cycles at 95◦C and a ﬁnal one-minute
cycle at 60◦C. A eukaryotic 18S rRNA endogenous control
probe/primer set (ABI) was used as an internal control
for RNA quality. Absolute quantitation of the amount of
mRNA in a given sample was determined using a 12-point
standardcurvegeneratedwith4-foldserialdilutions,starting
at 20000fg, of cDNA containing the gene of interest.
3. Results
3.1. Kinetic Analysis of the Metabolic Parameters in Mice on
an HF/CH Diet. DIO mice became obese after consuming
a diet containing 45% fat and 0.12% cholesterol (HF/CH),
with the body weight (BW) signiﬁcantly increased by 3
weeks. By 27-weeks the BW was 120% above their original
weight (Figure 1(a)). Similar to body weight, total fat mass
(Figure 1(c)) increased steadily. Epididymal fat (EF) mass
was signiﬁcantly elevated early and peaked by 6-weeks
(Figure 1(b)) but then declined following a trend similar
to other reported data [28] and suggestive of a shift in fat
depots. No signiﬁcant change in lean mass (Figure 1(d))
relative to the Chow cohort was detected. Elevated levels
of leptin, insulin, and ALT, an indicator of liver damage,
were evident by 6-weeks and remained elevated in the
DIO mice compared to the control group at each time
point. Serum levels of CCL2 and IL-6 were signiﬁcantly
elevated at 16-weeks, while trending upwards at 6-weeks.
Nonsigniﬁcant increases in IL-10 were also detected from 6-
weeks throughout the study. A HF/CH diet had a minimal
eﬀect on serum IL-1β and TNFα levels (Table 2).
3.2. Progressive Inﬁltration of Pro-Inﬂammatory ATMs.
We employed a detailed ﬂow cytometric gating strat-
egy (Figure 2(a)) to evaluate adipose tissue macrophages.
Total leukocytes were identiﬁed by CD45. In DIO mice,
the proportion of these cells increased to ∼30% by 3
weeks (Figure 2(b)). Total macrophages were identiﬁed
as CD45+F480+CD11b+ cells after electronic removal of
lymphocytes identiﬁed by cell size and the surface anti-
gens CD3, B220, NK1.1, and Thy1.2. The proportion
of macrophages was signiﬁcantly increased in DIO mice
by 6-weeks and peaked by 16-weeks (Figure 2(c)). The
absolute numbers per mg of fat of both total leuko-
cytes and macrophages progressively increased in the DIO
cohort from 16 to 27-weeks. In control mice, there4 PPAR Research
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Figure 1: An HF/CH diet kinetically induced metabolic obesity. C57BL/6 mice were placed on Chow (circles and dashed lines) or a diet of
45% fat and 0.12% cholesterol (squares and solid line) for 3, 6, 16, or 27-weeks. Groups of n ≥ 7 were sacriﬁced at each time point for both
chow and HF/CH diets. Body weight (a), mg of epididymal fat (b), total fat (c), and lean (d) mass were all measured. Epididymal fat tissue
and blood from these animals were subsequently used for FACs analysis. Values represent the mean and SEM. Unpaired T test was used to
compare Chow to DIO (HF/CH diet cohort) at each time point; ∗P<. 05, ∗∗P<. 001, and ∗∗∗P<. 0001.
Table 2: Elevated serum metabolic parameters and inﬂammatory mediators in the DIO cohort.
6-weeks 16-weeks 27-weeks
Parameter CHOW DIO CHOW DIO CHOW DIO
Insulin, pg/ml 57.8 (41) 383.4 (76)∗ 710.9 (145) 2901.0 (716)∗ 1458 (446) 2602.5 (289)∗
ALT, U/ml 23.0 (1.1) 29.5 (2.0)∗ 29.1 (5.3) 174.2 (40.9)∗ 22.9 (1.9) 82.7 (11.6)∗
Leptin, ng/ml 0.69 (0.30) 58.8 (14.6)∗ 7.1 (1.5) 32.9 (12.5)∗ 4.6 (1.2) 57.0 (12.6)∗
CCL2, pg/ml 0 4.3 (1.1) 18.9 (2.4) 42.1 (3.4)∗ 168.6 (21) 234.7 (14.4)∗
IL-6, pg/ml 0 3.5 (0.6) 9.6 (0.7) 25.5 (7.7)# 32.7 (11.2) 54.1 (17)
TNF, pg/ml 15.9 (2.1) 19.9 (2.3) 13.2 (0.4) 13.2 (0.5) 1.6 (0.7) 1.5 (0.3)
IL-1b, pg/ml 15.9 (2.1) 19.9 (2.3) 34.8 (1.4) 37.4 (1.5) 0.9 (0.2) 1.1 (0.2)
IL-10, pg/ml 21.8 (9.2) 33.1 (6.8) 39.1 (1.8) 66.8 (16.4) 22.1 (7.3) 69.8 (33)
At each timepoint, mice from separate groups of animals were terminally bled (Chow n = 8–13 mice and the DIO n = 7–18 mice). Values represent the mean
and SEM. Mann-Whitney U test was used to compare Chow to DIO at each time point; ∗P<. 05 and #P<. 08.PPAR Research 5
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Figure 2: Progressive inﬁltration of pro-inﬂammatory ATMs assessed by ﬂow cytometry. The epididymal fat pads were isolated from
n ≥ 7 animals per group at each time point. The SVF was isolated and stained to identify total leukocytes (b), macrophages (c), the
pro-inﬂammatory (d) and resident (e) ATM subsets according to the gating strategy (a). The ratio of the pro-inﬂammatory ATMs over
the resident ATMs is a quick indicator of the phenotypic proﬁle of the SVF macrophages. Values represent the mean and SEM. The Chow
group is represented by circles and dashed lines and the DIO group on HF/CH diet is represented by squares and a solid line. Unpaired T
test was used to compare standard chow to DIO at each time point; ∗P ≤ .05, ∗∗P ≤ .01, and ∗∗∗P ≤ .001.
was a modest increase in the proportion of macrophages
at 16-weeks and in the absolute numbers per mg of fat
o ft o t a ll e u k o c y t e sa n dm a c r o p h a g e sa t2 7 - w e e k s( F i g u r e s
2(b) and 2(c)). In contrast to the macrophages, neutrophils
were monitored but constituted a small percentage (<7%)
of leukocytes and decreased over time (data not shown),
consistent with previously published data [29]a n dar o l ef o r
neutrophils in the early onset of disease.
Similar increases in macrophage accumulation were
observed in the EF pads by immunohistochemistry using
anti-F480, and also by geneexpression analysis of F480
and CD68 (see Supplementary Figure 1 available at doi:
10.1155/2010/970164) . Anti-F480 staining of the EF pad
from DIO mice showed an accumulation of macrophages
and multinucleated crown structures by 6-weeks which
were a predominant characteristic of adipose tissue by 16-
w e e k s .Af e wc r o w ns t r u c t u r e sw e r ed e t e c t e di nc o n t r o l
mice at 27-weeks (see Supplementary Figure 1(a) available at
doi:10.1155/2010/970164). Gene expression analysis of F480
and CD68 showed 2–4 fold induction of macrophages by
six weeks; macrophage accumulation peaked (7-8 fold) at
16-weeks. At 27-weeks the fold induction was smaller due6 PPAR Research
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Figure 3: Induction of inﬂammatory mediators in whole EF assessed by gene expression at 6, 16, and 27-weeks. Data represented as HF/CH
gene expression fold induction versus the Chow cohort for each time point. (n = 7–10 mice for Chow and n = 10–15 mice for the HF/CH
group). The light gray bars indicate the 6-week timepoint, the dark gray bars indicate 16-week timepoint, and the black bars indicate the
27-week timepoint. Statistical signiﬁcance was determined by a two tailed Welch t-test; ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001.
to the increased number of macrophages in the normal
Chow group (see Supplementary Figure 1(b) available at
doi:10.1155/2010/970164).
To further phenotype the macrophage content in the
HF/CH induced DIO model, we proﬁled the PI-ATM and
R-ATM. The total macrophages were delineated as either
PI-ATMs (CD11c+) or R-ATM (CD11c-) by the CD11c
marker. There was a modest increase in both the PI-ATM
and R-ATMs in DIO mice at 6-weeks, with a dramatic
increase in the percentage and number of the PI-ATM at
16-weeks (Figures 2(d) and 2(e)). These data correlated
with a dramatic increase in the PI/R-ATM ratio, indicating
a preferential accumulation of PI-ATM (Figure 2(f)). In
contrast, the normal chow mice exhibited a gradual increase
in their R-ATM (Figure 2(e)) and a consistently low PI/R-
ATM ratio (Figure 2(f)).
3.3. Mediator Proﬁle of the Epididymal Tissue, SVF, and Sorted
Cells. Similar to the mediator proﬁle in serum, elevations
in mRNA for CCL2, IL-6, and IL-10 in EF tissue were
observed in DIO mice. Detectable increases in TNFα,I L - 1 β,
and TGFβ expression in EF were observed as well (Figure 3).
Spontaneous mediator production from ex vivo DIO SVF
culturesalsoshowedelevatedlevelsofIL-6,IL-10,andTNFα,
with a minimal increase in IL-1β (Figure 6(b)). To determine
the contribution of ATMs to mediator production, PI-
A T Ma n dR - A T Mf r o mD I Om i c ew e r es o r t e db a s e do n
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Figure 4:Pro-inﬂammatoryATMsexpressbothpro-andanti-inﬂammatorymediatorsasassessedbygeneexpression.Fourcellpopulations
were sorted from the SVF from mice (n ≥ 3) fed an HF/CH diet for approximately 16-weeks. The pro-inﬂammatory ATMs (PI-ATM:
CD45+F480+CD11c+), resident ATMs (R-ATM: CD45+F480+CD11c−), a CD45+ unknown population (A: CD45+F480−CD11c+), and
aC D 4 5 − unknown population (B: CD45 Thy1.2+Ly6C+/−CD11b−) were sorted and analyzed for gene expression from two independent
sorts.
(Figure 4). In addition to CD11c, PI-ATMs expressed ele-
vated mRNA levels of the characteristic pro-inﬂammatory
mediators, including TNFα, IL-6, and IL-1β. These cells also
expressed elevated levels of ApoE, IL-10, and TGFβ.L Y V E - 1
was the only gene expressed at elevated levels in R-ATMs.
3.4. Novel Cellular Inﬁltrates in the Epididymal Fat. Besides
macrophages, SVF has been proposed to contain sev-
eral other cell subsets including preadipocytes, epithe-
lial, and endothelial cells [16, 30]. Our gating strat-
egy led to the detection of two additional populations
(Figure 2(a)). The ﬁrst population, identiﬁed as CD45+
F480−CD11b+ CD11c+ (A), represented 10–20% of the
CD45 population. The second population, identiﬁed as
CD45−F480−CD11b−Ly6C+/−Thy1.2+ (B), represented
5–10% of total cells of the SVF. Gene expression proﬁling
showed that population A expressed IL-1β and IL-6 at levels
similar to those detected in PI-ATM, whereas population B
expressed IL-6 at 48 fold and CCL2 at 20-fold higher levels
relative to PI-ATM (Figure 4). Clearly, populations A and B
warrant further characterization to determine their role in
the described obesity model.8 PPAR Research
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Figure 5: Rosiglitazone reduced the pro-inﬂammatory ATM inﬁltration in epididymal fat. Animals were put on Chow or an HF/CH diet
for 12 weeks. Then Rosiglitazone at 5mg/kg or vehicle was supplemented in the food for drug treatment the ﬁnal 6-weeks. (a)–(d). Flow
cytometry was performed at the termination of the study at 18 weeks (n ≥ 6 mice/group). (a) Total leukocyte inﬁltration was assessed by
CD45. (b) Total macrophage inﬁltration was determined by CD45+F480+CD11b+ cells. Finally total macrophages were subdivided into
two groups the (c) pro-inﬂammatory CD45+F480+CD11b+CD11c+ ATMs and (d) resident CD45+F480+CD11b+CD11c ATMs. (e) The
ratio of the pro-inﬂammatory ATMs to resident ATM populations was reduced with Rosiglitazone. Values represent the mean and SEM. The
groups are represented by the following symbols: circles (Chow), squares (DIO), and diamonds (DIO/Rosi). One way ANOVA (Bonferroni
multiple comparison) was used to compare Chow to DIO and DIO to DIO/Rosi at each time point; ∗P<. 05 and ∗∗∗P<. 001.
3.5. Rosiglitazone Attenuated the Inﬂammatory Mediator Pro-
ﬁle of the Epididymal Fat. Rosiglitazone treatment reduced
hyperinsulinemia (DIO 4510 +/− 490pg/ml: DIO-Rosi
2170 +/− 620pg/ml), serum CCL2 levels (DIO 84.2 +/−
0.18pg/ml: DIO-Rosi 47.3 +/− 4.6pg/ml) and SVF mediator
production of IL-6, TNFα,I L - 1 β and IL-10 (Figure 6(b)).
Rosiglitazone treatment signiﬁcantly decreased the percent-
age and absolute number of total leukocytes (Figure 5(a))PPAR Research 9
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Figure 6: Rosiglitazone reduced macrophage and pro-inﬂammatory markers by gene expression as well as ex vivo spontaneous mediator
production. (a) Gene expression of macrophage markers was analyzed from the epididymal fat pads. Data is represented as DIO gene
expression fold induction versus the chow cohort or DIO animals treated with Rosiglitazone versus the DIO cohort (n = 8 mice/group).
Statistical signiﬁcance was determined by a two-tailed Welch t-test; ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001. (b) Stromal vascular cells were
isolated from the EF and incubated ex vivo. Spontaneous mediator production was assessed (n = 8 mice/group). Values represent the mean
and SEM. Mann-Whitney U test was used to compare standard chow to DIO or DIO to DIO/rosiglitazone; ∗P<. 05 and ∗P<. 01.
and total F480+ macrophages (Figure 5(b)) in the fat tissue.
Of the macrophages, rosiglitazone preferentially decreased
the proportion of PI-ATM (Figure 5(c)) and elevated
the proportion of R-ATM (Figure 5D), which ultimately
decreased the PI/R-ATM ratio (Figure 5(e)). Similarly,
decreased macrophage accumulation in the rosiglitazone
cohort was supported by decreased mRNA levels of F480,
CD68 and CD11c in the epididymal fat (Figure 6(a)). The
newly identiﬁed populations A and B were not followed in
the current rosiglitazone study but will be pursued pending
further cell characterization.
3.6. Rosiglitazone Modulates the HF/CH Diet-Induced Blood
Monocytes. Blood monocytes were monitored as a potential
biomarker [6, 27, 31, 32]. Similar to the gating strategy for
the epididymal fat, CD45 was used to delineate the leukocyte
population. Subsequently, Ly6G, CD3, B220, NK1.1, and
Thy1.2 were used to identify and electronically discard the
neutrophils and T, B, and NK cells (Figures 7(a) and 7(b)).
Monocytes were then identiﬁed by F480 and Ly6C. Previous
reports have classiﬁed Ly6CHi as pro-inﬂammatory and
Ly6Clo/int as anti-inﬂammatory monocytes [32]. Through-
out the kinetic study, there is an upward trend in the propor-
tion of both blood monocyte populations in the DIO cohort
compared to chow, although the increase only reached
signiﬁcance at 6-weeks (Figures 7(c) and 7(d)). Assessment
of the absolute numbers of blood monocytes revealed no
kinetic diﬀerences observed between the groups (Figures
7(c) and 7(d)). Despite the very modest alteration in the
proportion of circulating monocytes in mice on an HF/CH
diet, rosiglitazone attenuated the increase in the proportion
of Ly6CHi and Ly6Clo/int monocytes (Figures 7(e) and 7(f)).
4. Discussion
The goal of this study was to assess the eﬀect of an
HF/CH diet on the cellular and molecular parameters in10 PPAR Research
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Figure 7: Rosiglitazone can modulate a trend for an elevation in the percentage of monocytes. Whole blood was stained and monocytes
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DIO mice and the eﬀect of an insulin sensitizing agent,
rosiglitazone, on these parameters. Changes in metabolic
parameters occurred as early as 6-weeks in DIO mice as
evidenced by hyperinsulinemia, increased leptin levels and
modestly increased levels of pro-inﬂammatory mediators,
including CCL2 and IL-6, in the serum and in the EF pad.
Despitetheseearlychanges,dramaticmetabolicchangesonly
occurred at and beyond 16-weeks.
Cell inﬁltration is one of the hallmarks of inﬂammation;
we observed an increase in total leukocytes within the SVF
by 3 weeks in DIO mice. Within the leukocyte population,
the percentage of total macrophages signiﬁcantly increased
by 6-weeks which was corroborated by F480 and CD68 gene
expression data and F480 immunostaining of EF tissue.
However, the peak of macrophage accumulation occurred
at 16 to 27-weeks correlating with maximal insulin levels.
In the DIO mice, although there was a modest increase in
the proportion of both PI-ATM and R-ATMs at 6-weeks,
there was a dramatic increase in the proportion and absolute
numbers of PI-ATM at 16 to 27-weeks. This correlated with
signiﬁcantincreaseinthePI/R-ATMratioindicativeofapro-
inﬂammatory microenvironment. Thus, as hypothesized,PPAR Research 11
the HF/CH diet led to an early inﬂammatory response with
kinetics paralleling the peak of the insulin levels and liver
damage (ALT).
Analysis of the EF tissue or spontaneous mediator
production from cultured SVF cells derived from DIO
mice after 16-weeks on the HF/CH diet revealed an induc-
tion of the various pro-inﬂammatory mediators such as
CCL2, TNFα, IL-6 or IL-1β and the pleiotropic mediator,
IL-10. To determine if the macrophages were the pri-
mary contributors to this mediator production from the
SVF, we sorted four populations: PI-ATM, R-ATM and
two additional populations and evaluated their mediator
proﬁle by gene expression. The two additional popula-
tions were CD45+ F480−CD11b+ CD11c+ cells (A) and
CD45−F480−CD11b−Ly6C+/−Thy1.2+ cells (B), which
express surface antigens potentially associated with other
myeloid or hematopoietic cells.
Our data indicates that both macrophages and novel
cell populations within the SVF fraction contribute to the
inﬂammatory state of the adipose tissue in DIO mice. Gene
expression proﬁling of sorted macrophage subsets conﬁrmed
that the PI-ATMs had elevated message levels of the pro-
inﬂammatory mediators, including TNFα, IL-6, and IL-
1β,a sw e l la sT G F β, a ﬁnding consistent with human
ATM data [15, 16]. In addition, the PI-ATM also expressed
elevated levels of IL-10 and ApoE, which are often perceived
as anti-inﬂammatory mediators. However, both IL-10 and
ApoE are pleiotropic molecules and they could be exerting
pro-inﬂammatory eﬀects. For example, overexpression of
IL-10 in islet cells in a nonobese diabetic mouse model
exacerbates diabetes [33] and, recent data indicate that ApoE
can stimulate dendritic cells to present lipids [34]. These
mediators could be having pro-inﬂammatory roles or they
could be coexpressed as a mechanism to counter-regulate
the pro-inﬂammatory state. Similar to our data some report
the mediator proﬁle of PI-ATMs from mice on HF or
Chow diets showed expression of TNFα, IL-6 and/or IL-10
[14] or a subset of these mediators [12, 13, 31]. Overall,
from the sorted SVF populations, the PI-ATMs described in
this manuscript are highly metabolically active, expressing
multiple pro-inﬂammatory mediators (IL-1β,I L - 6 ,T N F α),
growth factors (TGFβ) and pleiotropic mediators (APOE
and IL-10). Although the described ATMs could not be
deﬁnitively classiﬁed as pro or anti-inﬂammatory, these data
areconsistentwiththehumanreportsindicating thathuman
ATMs [10, 11, 16] and cultured human SVF cells showed
elevated levels of IL-1β,T N F α, IL-6 and CCL2 as well as IL-
10 [11, 15]. With the exception of LYVE-1, a gene recently
associated with tissue angiogenesis [35] or remodeling [16],
the R-ATM described herein expressed lower levels of most
mediators relative to the PI-ATM, despite reports of elevated
levels of IL-10 [13]a n dA p o E[ 12, 31] in these cells.
Some of the discrepancies between the ATM subsets
described herein and those of previous studies could be
due to diﬀerences in the diets, activation or diﬀerentiation
state of the sorted populations, or due to the plasticity of
macrophage populations [36, 37]. Alternatively, diﬀerences
in the stringency of the gating method and sort strategies
could account for the discrepancies. Our data clearly indi-
cated that there are additional populations of cells that can
be identiﬁed in the adipose tissue that could contribute to
mediator production.
As stated previously, using our gating strategy, two
additional inﬂammatory cell populations were identiﬁed.
Population B (CD45−Thy1.2+) was a prominent population
representing 5–10% of the total SVF. It was observed that
this population expressed extremely high levels of IL-6 and
CCL2 that far exceeded those of the PI-ATMs. Based on
this initial characterization, these cells could represent any
of several cell types including newly recruited monocytes,
cells of endothelial origin which can secrete CCL2 and IL-
6[ 15, 16], stromal cells as seen in human adipose tissue [30,
38–41], early hematopoietic derived cells, or preadipocytes.
[30, 42]. Population A (CD45+F480−CD11c+) represented
10–20% of the CD45 cells of the SVF and expressed levels
of IL-6 and IL-1β similar to those of PI-ATMs. These cells,
especially population B, contribute to the pro-inﬂammatory
state of the fat tissue. Clearly, as indicated by the proﬁling
of populations A and B, the PI-ATM and R-ATM are
not the only cells producing inﬂammatory mediators in
the SVF. Future studies are being designed to further the
characterization and to determine if anti-inﬂammatory or
obesity-related drugs alter these populations.
The insulin sensitizing agent, rosiglitazone, is a PPARγ
agonist used in the clinic to treat type II diabetes and
recently has been reported to aﬀect the phenotypic switch
of macrophages from a pro to an anti-inﬂammatory proﬁle
as well as to aﬀect macrophage inﬁltration into the EF
pad [27]. Consistent with reports from clinical studies [24],
treatment of DIO mice on the HF/CH diet with rosiglitazone
increased the body weight and decreased hyperinsulinemia
demonstrating the drug’s insulin sensitizing eﬀects (data
not shown). These changes in metabolic parameters were
paralleled by changes in the pro-inﬂammatory state of the
mice. There was a reduction in spontaneous mediator pro-
duction from cultured SVF cells from rosiglitazone treated
DIO mice which correlated with a decrease in macrophage
accumulation.
Gene expression analysis indicated a reduction in the
macrophage markers, F480 and CD68, as well as CD11c in
total adipose tissue from rosiglitazone treated DIO mice.
Flow cytometry analysis corroborated and extended these
ﬁndings by revealing that rosiglitazone treatment signiﬁ-
cantly reduced the PI-ATMs, lowering the PI/R-ATM ratio to
a level close to that observed for the normal Chow cohort.
Our data supports the theory that rosiglitazone switches
the proﬁle of the ATMs from a pro-inﬂammatory to a
more anti-inﬂammatory or resting state [43]. Alternatively,
rosiglitazone could alter the balance of cell recruitment and
migratory clearance of ATMs; in an atherosclerosis model
reduced emigration of myeloid derived cells out of plaques
contributed to the disease pathology [44].
In addition to the analysis of adipose tissue ATM,
peripheral blood monocytes were analyzed as a potential
biomarker for obesity and insulin resistance in preclinical
and clinical studies. In the kinetic study, we detected a
signiﬁcant elevation in both the pro-inﬂammatory (Ly6Chi
F480+/−) and homeostatic (Ly6Clo/− F480+/−)m o n o c y t e12 PPAR Research
populations at 6-weeks. At later time points, there was
a trend only for an increase in the percentages but not
in number of monocytes consistent with previous reports
indicating modest but signiﬁcant elevations of monocyte
populations [27, 32]. Continual emigration from the bone
marrow coupled with the simultaneous and continual inﬂux
into the fat depots or sites of inﬂammation may account
for the very modest increase in monocytes throughout the
treatment period. Despite the limited modulation in mono-
cytes, at 18 weeks post-HF/CH diet, rosiglitazone induced
a modest but nonsigniﬁcant reduction in the percentage of
both monocyte populations. Although it remains possible
that rosiglitazone may have had a more dramatic eﬀect on
monocyte populations at an earlier time point, 18 weeks
represents the peak of the metabolic changes and PI-ATM
inﬁltration. Due to the modest therapeutic window for
modulation of monocytes, we concluded that monitoring of
monocyte populations in the blood would be inadequate to
f o l l o wa sab i o m a r k e ru n l e s sam o r ed r a m a t i cm o d u l a t i o no f
m o n o c y t e si so b s e r v e di nh u m a ns u b j e c t s .
In conclusion, an HF/CH-like diet rich in fat and choles-
terol induces obesity which correlates with an inﬂammatory
state as exhibited by a rapid increase in epididymal fat
pad mass, hyperinsulinemia, macrophage inﬁltration and
mediator production in the fat depots. The increased ratio of
PI/R-ATMs and the production of many pro-inﬂammatory
mediators correlated with the peak of disease induced by the
HF/CH diet as evidenced by maximal insulin levels at 16-
weeks and are indicative of an inﬂammatory state in DIO
mice. At the peak of disease, rosiglitazone attenuates the
inﬂammatory response as exempliﬁed by a reduction in the
ratio of PI/R-ATMs and the production of multiple media-
tors. Lastly, a very intriguing ﬁnding was the identiﬁcation
of a novel population in the SVF that expressed very high
mRNA levels of IL-6 and CCL2 exceeding those observed in
the PI-ATM. This population warrants additional investiga-
tion as it could signiﬁcantly impact the inﬂammatory state
in DIO mice and potentially in human obese and diabetic
subjects. This DIO mouse model induced with HF/CH is
an appropriate model for characterization of therapeutics
targeted not only for the metabolic parameters of the
syndrome but also for the low-level chronic inﬂammatory
response that is induced by the diet.
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